HC Wainwright Forecasts CorMedix’s Q3 Earnings (NASDAQ:CRMD)

CorMedix Inc (NASDAQ:CRMD) – HC Wainwright boosted their Q3 2025 EPS estimates for shares of CorMedix in a report released on Thursday, September 25th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $0.43 per share for the quarter, up from their prior forecast of $0.33. HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix’s FY2027 earnings at $2.17 EPS and FY2029 earnings at $2.67 EPS.

CorMedix (NASDAQ:CRMD) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.08. The business had revenue of $39.74 million during the quarter, compared to the consensus estimate of $29.88 million. CorMedix had a return on equity of 42.73% and a net margin of 42.11%.The business’s revenue was up 4830.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.25) earnings per share.

A number of other brokerages have also issued reports on CRMD. D Boral Capital lowered CorMedix from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 30th. Wall Street Zen raised shares of CorMedix from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 13th. Needham & Company LLC upped their price objective on shares of CorMedix from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, June 24th. D. Boral Capital lowered shares of CorMedix from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Finally, Royal Bank Of Canada raised shares of CorMedix from an “outperform” rating to a “moderate buy” rating and upped their price target for the stock from $13.00 to $17.00 in a research note on Friday, June 20th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

CorMedix Trading Up 1.6%

Shares of NASDAQ CRMD opened at $11.30 on Friday. CorMedix has a 12-month low of $5.60 and a 12-month high of $17.43. The stock has a 50 day simple moving average of $12.35 and a 200-day simple moving average of $11.30. The company has a market cap of $882.07 million, a PE ratio of 15.07 and a beta of 1.76.

Institutional Investors Weigh In On CorMedix

Hedge funds have recently modified their holdings of the stock. Canada Pension Plan Investment Board purchased a new stake in CorMedix during the second quarter valued at about $42,000. SBI Securities Co. Ltd. lifted its stake in CorMedix by 699.7% during the first quarter. SBI Securities Co. Ltd. now owns 8,685 shares of the company’s stock valued at $54,000 after buying an additional 7,599 shares in the last quarter. USA Financial Formulas purchased a new stake in shares of CorMedix in the 2nd quarter valued at approximately $55,000. Essex Financial Services Inc. purchased a new stake in shares of CorMedix in the 1st quarter valued at approximately $63,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of CorMedix in the 1st quarter valued at approximately $66,000. 34.18% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at CorMedix

In other news, COO Elizabeth Hurlburt sold 41,121 shares of the stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $13.08, for a total transaction of $537,862.68. Following the completion of the sale, the chief operating officer owned 176,990 shares in the company, valued at approximately $2,315,029.20. This represents a 18.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Alan W. Dunton sold 10,000 shares of the stock in a transaction on Friday, September 12th. The shares were sold at an average price of $13.13, for a total value of $131,300.00. Following the sale, the director owned 40,250 shares of the company’s stock, valued at $528,482.50. This trade represents a 19.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 163,997 shares of company stock valued at $2,163,617 in the last ninety days. Company insiders own 5.30% of the company’s stock.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.